<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04097821</url>
  </required_header>
  <id_info>
    <org_study_id>CINC424H12201</org_study_id>
    <secondary_id>2019-000373-23</secondary_id>
    <nct_id>NCT04097821</nct_id>
  </id_info>
  <brief_title>Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients</brief_title>
  <acronym>ADORE</acronym>
  <official_title>A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety, pharmacokinetics and preliminary
      efficacy of combinations treatment of ruxolitinib with 3 novel compounds: siremadlin,
      crizanlizumab and MBG453 in myelofibrosis (MF) subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2019</start_date>
  <completion_date type="Anticipated">June 10, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 16, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities within the first 2 cycles</measure>
    <time_frame>Baseline to the end of Cycle 2 (8 weeks)</time_frame>
    <description>Incidence and severity of dose limiting toxicities within the first 2 cycles (8 weeks) in Part 1 of the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate at the end of cycle 6</measure>
    <time_frame>Baseline to the end of Cycle 6 (24 weeks)</time_frame>
    <description>Composite of anemia improvement (hemoglobin level) and no spleen volume progression and no symptom worsening in Part 2 and Part 3 of the study. For a subject to be considered a responder, all three components of the composite have to be fulfilled</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving an improvement in hemoglobin level of ≥ 1.5 g/dL from baseline</measure>
    <time_frame>Baseline to the end of Cycle 6 (24 weeks), and end of Cycle 12 (48 weeks)</time_frame>
    <description>Proportion of subjects achieving an improvement in hemoglobin level of at least &gt;= 1.5 g/dL from baseline at each time point in Part 2 and Part 3 of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving an improvement in hemoglobin level of at least &gt;= 2.0 g/dL from baseline</measure>
    <time_frame>Baseline to the end of Cycle 6 (24 weeks), and end of Cycle 12 (48 weeks)</time_frame>
    <description>Proportion of subjects achieving an improvement in hemoglobin level of at least &gt;= 2.0 g/dL from baseline at each time point in Part 2 and Part 3 of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in spleen length from baseline</measure>
    <time_frame>Baseline to day 1 and day 15 of Cycle 1, 2 and 3 (each cycle is 28 days), day 1 of all subsequent cycles, and the end of treatment (approx 12 cycles = 48 weeks)</time_frame>
    <description>Change in spleen length measured in centimeters by manual palpation summarized at each time point using descriptive statistics in Part 2 and Part 3 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in spleen volume from baseline</measure>
    <time_frame>Baseline to the end of Cycle 6 (24 weeks), the end of Cycle 12 (48 weeks) and at the end of treatment if not performed in the past 12 weeks (up to 48 weeks)</time_frame>
    <description>Change in spleen volume measured by magnetic resonance imaging (MRI) or computed tomography (CT) summarized at each time point using descriptive statistics, in Part 2 and Part 3 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptoms of MFSAF v4.0 from baseline</measure>
    <time_frame>Baseline to day 1 of Cycle 1, day 1 of all subsequent cycles of treatment (each cycle is 28 days), as well as the end of treatment visit (approximately 52 weeks)</time_frame>
    <description>Change in total symptom scores (TSS) assessed by the Myelofibrosis (MF Symptom Assessment Form version 4.0 (MFSAF v4.0) at each time point in Part 2 and Part 3 of the study. The MFSAF v4.0 questionnaire focuses on the 7 core symptoms of MF: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety and bone pain. Subjects record symptom severity at it worst for each of the 7 symptoms on an 11-point numeric rating scale, from 0 (absent) to 10 (worst imaginable). The Total Symptom Score (TSS) is the sum of all the scores for all 7 symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in symptoms of EORTC QLQ-C30 from baseline</measure>
    <time_frame>Baseline to day 1 of Cycle 1, day 1 of all subsequent cycles of treatment (each cycle is 28 days), as well as the end of treatment visit (approximately 52 weeks)</time_frame>
    <description>Change in symptom scores assessed by European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire (EORTC QLQ C-30) at each time point in Part 2 and Part 3 of the study. The EORTC QLQ-C30 includes 5 functional scales (physical, emotional, social, role, cognitive), eight symptom scales (fatigue, pain, nausea/vomiting, constipation, diarrhea, insomnia, dyspnea, and appetite loss), as well as global health/quality-of-life and financial impact. Subjects respond according to the past week recall period, with the exception of the first 5 questions that represent physical functioning and capture the subject's current status. Raw scores are linearly converted to a 0-100 scale. For functional and global health status/QoL higher scores indicate better QoL and level of functioning; for symptom scales, higher scores indicate greater level of symptoms or difficulties.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival, per progressive splenomegaly, accelerated phase, deteriorating cytopenia, leukemic transformation or death from any cause</measure>
    <time_frame>Baseline to disease progression, which is up to 24 weeks for Part 1 or through study completion, an average of 1 year, for Part 2 and Part 3</time_frame>
    <description>Progressive splenomegaly is assessed by increasing spleen volume (by MRI/CT) of ≥ 25% from baseline. Accelerated phase: a circulating peripheral blood blast content of &gt; 10% but &lt; 20% confirmed after 2 weeks.
Deteriorating cytopenia (dCP) independent from treatment defined for all patients by platelet count &lt; 35 x10^9/L or neutrophil count &lt; 0.75 x 10^9/L that lasts for at least 4 weeks.
Leukemic transformation, a peripheral blood blast content of ≥ 20% associated with an absolute blast count of ≥ 1x10^9/L that lasts for at least 2 weeks or a bone marrow blast count of ≥ 20%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving an impovement in bone marrow fibrosis of ≥ 1 grade from baseline</measure>
    <time_frame>Baseline to the end of Cycle 6 (24 weeks), the end of Cycle 12 (48 weeks) and at the end of treatment if not performed in the past 12 weeks (up to 48 weeks)</time_frame>
    <description>Proportion of subjects achieving an improvement in bone marrow fibrosis of &gt;= 1 grade at each time point will be summarized in Part 2 and Part 3 of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the Plasma Concentration versus Time Curve (AUC)</measure>
    <time_frame>Days 1, 2, 5 and 6 of Cycle 1 and 2 for siremadlin and ruxolitinib, and Cycle 1 and Cycle 3 for crizanlizumab and MBG453 (one cycle is 28 days)</time_frame>
    <description>Summary statistics of AUC for each investigational drug in Part 1, Part 2 and Part 3 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum (peak) observed plasma drug concentration (Cmax)</measure>
    <time_frame>Days 1, 2, 5 and 6 of Cycle 1 and 2 for siremadlin and ruxolitinib, and Cycle 1 and Cycle 3 for crizanlizumab and MBG453 (one cycle is 28 days)</time_frame>
    <description>Summary statistics of Cmax for each investigational drug in Part 1, Part 2 and Part 3 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum (peak) plasma, blood, serum or other body fulid drug concentration after single dose administration (Tmax)</measure>
    <time_frame>Days 1, 2, 5 and 6 of Cycle 1 and 2 for siremadlin and ruxolitinib, and Cycle 1 and Cycle 3 for crizanlizumab and MBG453 (one cycle is 28 days)</time_frame>
    <description>Summary statistics of Tmax for each investigational drug in Part 1, Part 2 and Part 3 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration versus time profile</measure>
    <time_frame>Days 1, 2, 5 and 6 of Cycle 1 and 2 for siremadlin and ruxolitinib, and Cycle 1 and Cycle 3 for crizanlizumab and MBG453 (one cycle is 28 days)</time_frame>
    <description>Concentration versus time profile for each investigational drug in Part 1, Part 2 and Part 3 of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and/or concentration of anti-drug antibody</measure>
    <time_frame>Baseline to 105 days after last study drug adminstration for crizanlizumab or to 90 days after last study drug administration for MBG453</time_frame>
    <description>The presence and titer of anti-drug antibodies will be listed by subject and summarized using descriptive statistics for both crizanlizumab and MBG453.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Part 1 Arm 1: Ruxolitinib + Siremadlin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of siremadlin added to existing stable dose of ruxolitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Arm 2: Ruxolitinib + Crizanlizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Safety run-in of crizanlizumab added to existing stable dose of ruxolitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Arm 3: Ruxolitinib + MBG453</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Safety run-in of MBG453 added to existing stable dose of ruxolitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm 1: Ruxolitinib + Siremadlin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Siremadlin added to existing stable dose of ruxolitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm 2: Ruxolitinib + Crizanlizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Crizanlizumab added to existing stable dose of ruxolitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm 3: Ruxolitinib + MBG453</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MBG453 added to existing stable dose of ruxolitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm 4: Ruxolitinib monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Existing stable dose of ruxolitinib as control for Part 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 Arm 1: Ruxolitinib + Compound X</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Compound from Part 2 (to be confirmed) added to existing stable dose of ruxolitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 Arm 2: Ruxolitinib cessation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Compound from Part 2 added to existing stable dose of ruxolitinib for 3 cycles followed by compound monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3 Arm 3: Ruxolitinib monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Existing stable dose of ruxolitinib as control for Part 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>5 mg tablets for oral use</description>
    <arm_group_label>Part 1 Arm 1: Ruxolitinib + Siremadlin</arm_group_label>
    <arm_group_label>Part 1 Arm 2: Ruxolitinib + Crizanlizumab</arm_group_label>
    <arm_group_label>Part 1 Arm 3: Ruxolitinib + MBG453</arm_group_label>
    <arm_group_label>Part 2 Arm 1: Ruxolitinib + Siremadlin</arm_group_label>
    <arm_group_label>Part 2 Arm 2: Ruxolitinib + Crizanlizumab</arm_group_label>
    <arm_group_label>Part 2 Arm 3: Ruxolitinib + MBG453</arm_group_label>
    <arm_group_label>Part 2 Arm 4: Ruxolitinib monotherapy</arm_group_label>
    <arm_group_label>Part 3 Arm 1: Ruxolitinib + Compound X</arm_group_label>
    <arm_group_label>Part 3 Arm 2: Ruxolitinib cessation</arm_group_label>
    <arm_group_label>Part 3 Arm 3: Ruxolitinib monotherapy</arm_group_label>
    <other_name>INC424, Jakavi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Siremadlin</intervention_name>
    <description>10 mg, 20 mg, or 40 mg capsules for oral use</description>
    <arm_group_label>Part 1 Arm 1: Ruxolitinib + Siremadlin</arm_group_label>
    <arm_group_label>Part 2 Arm 1: Ruxolitinib + Siremadlin</arm_group_label>
    <other_name>HDM201</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizanlizumab</intervention_name>
    <description>100 mg/mL concentrate for infusion for intravenous use</description>
    <arm_group_label>Part 1 Arm 2: Ruxolitinib + Crizanlizumab</arm_group_label>
    <arm_group_label>Part 2 Arm 2: Ruxolitinib + Crizanlizumab</arm_group_label>
    <other_name>SEG101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MBG453</intervention_name>
    <description>100 mg/mL concentrate for infusion for intravenous use</description>
    <arm_group_label>Part 1 Arm 3: Ruxolitinib + MBG453</arm_group_label>
    <arm_group_label>Part 2 Arm 3: Ruxolitinib + MBG453</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects have diagnosis of primary myelofibrosis (PMF) according to the 2016 World
             Health Organization (WHO) criteria, or diagnosis of post-essential thrombocythemia
             (ET) (PET-MF) or post-polycythemia vera (PV) myelofibrosis (PPV-MF) according to the
             International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) 2007
             criteria

          -  Palpable spleen of at least 5 cm from the left costal margin (LCM) to the point of
             greatest splenic protrusion or enlarged spleen volume of at least 450 cm3 per MRI or
             CT scan at baseline (a MRI/CT scan up to 8 weeks prior to first dose of study
             treatment can be accepted).

          -  Have been treated with ruxolitinib for at least 24 weeks prior to first dose of study
             treatment

          -  Are stable (no dose adjustments) on the prescribed ruxolitinib dose (between 5 and 25
             mg twice a day (BID)) for ≥ 8 weeks prior to first dose of study treatment

        Exclusion Criteria:

          -  Not able to understand and to comply with study instructions and requirements.

          -  Received any investigational agent for the treatment of MF (except ruxolitinib) within
             30 days of first dose of study treatment or within 5 half-lives of the study
             treatment, whichever is greater

          -  Peripheral blood blasts count of &gt; 10%.

          -  Received a monoclonal antibody (Ab) or immunoglobulin-based agent within 1 year of
             screening, or has documented severe hypersensitivity reactions/immunogenicity (IG) to
             a prior biologic

          -  Splenic irradiation within 6 months prior to the first dose of study drug

          -  Received blood platelet transfusion within 28 days prior to first dose of study
             treatment.

        Other protocol-defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68305</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <state>HUN</state>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 17, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myelofibrosis</keyword>
  <keyword>ruxolitinib</keyword>
  <keyword>INC424</keyword>
  <keyword>siremadlin</keyword>
  <keyword>HDM201</keyword>
  <keyword>crizanlizumab</keyword>
  <keyword>SEG101</keyword>
  <keyword>MBG453</keyword>
  <keyword>platform study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_url>https://www.clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

